"Cancer Treatment Without Damaging Healthy Cells: Development of 'Smart Antibody' Technology"
A switchable "smart antibody" technology that enables immune cells to selectively attack cancer cells at the desired time and location has been developed in South Korea. The biggest advantage of smart antibody technology is that it reduces the side effects of conventional "CAR-T" therapies, which attack as soon as they recognize cancer cells, causing damage to healthy cells as well. CAR-T is a type of cell therapy that genetically engineers a patient's immune cells to attack cancer cells.
KAIST announced on May 27 that the research team led by Distinguished Professor Won Do Heo of the Department of Biological Sciences has developed the "Extrabody" platform, which controls antigen recognition outside the cell using light and chemical stimuli.
(From left) Professor Wondo Hur, Dr. Yuri Kwon (first author), Dr. Daseul Yoo (co-first author). KAIST
View original imageThe research team separated the antibody into two fragments and designed them to recombine only when exposed to external stimuli. Unlike ordinary antibodies, which bind to antigens upon creation, the key feature of this system is that the separated antibody fragments only recombine and recognize antigens in the presence of light or chemicals.
This result moves beyond the traditional approach, in which antibody systems are "always on" and act unconditionally, by implementing an antibody platform that can be activated selectively only when needed.
To implement this platform, the team established two separate systems: one that responds to light and another that responds to chemicals. They confirmed the potential to apply these systems to fluorescent proteins and to EGFR (epidermal growth factor receptor) and HER2 (human epidermal growth factor receptor 2) proteins, which are mainly expressed on the surface of cancer cells.
In experiments, Extrabody showed that antigen binding was selectively activated only in the presence of external stimuli, and the same principle applied to various antibody structures. This demonstrates that Extrabody can serve as a modular platform (a technological structure that can be expanded to multiple targets and functions) applicable to a wide range of targets and antibody types.
The research team also demonstrated that Extrabody can regulate not only antigen recognition but also intercellular interactions. When exposed to light stimulation, cells made contact and transferred antigens to each other, while such responses were rarely observed in the absence of stimulation.
When Extrabody was applied to synthetic receptors (synthetic biology technology designed to induce cellular responses only when specific signals are received) and CAR systems (technology designed to enable immune cells to recognize and attack specific cancer cells), the researchers could implement a "dual-lock" mechanism, where intracellular signaling was activated only when both light and antigen were present simultaneously.
Through this, the research team explained that it became possible to precisely control gene expression, cytokine secretion (proteins used for signaling between immune cells), and immune cell activation. In actual T cell experiments, it was confirmed that cancer cells were selectively attacked only in the presence of light stimulation.
The research team expects that this technology will help establish a new strategy for reducing side effects such as unintended immune activation and attacks on healthy cells—issues that have been pointed out with existing CAR-T cell therapy.
Professor Heo said, "Extrabody is a new platform that enables precise control of cellular target recognition at the desired time and location using external stimuli. The research team expects this technology to serve as a core foundational technology for improving the safety and precision of next-generation immunotherapies and cell-based therapeutic technologies in the future."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, Dr. Yuri Kwon and Dr. Daseul Yoo of the Department of Biological Sciences at KAIST participated as co-first authors of this study. The research results were published online in the international journal 'Cell Chemical Biology' on May 7.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.